PubMed Health⌕ Search

PubMed · 12386844

A concept for synthesis planning in solid-state chemistry.

Abstract

There is a widely-held belief that the preparation of new solid-state compounds based on rational design is not possible. Herein, we present a concept that points the way towards a rational design of syntheses in solid-state chemistry. The foundation of our approach is the representation of the whole material world, that is, the known and not-yet-known compounds, on an energy landscape, which gives information about the free energies of these compounds. From this it follows that all chemical compounds capable of existence are present on this landscape. Thus the chemical synthesis always corresponds to the discovery of compounds, not their creation. Consequently, the first step in planning a synthesis can and must be to identify a synthesizable compound. Up to now, materials capable of existence are discovered in the course of an experimental exploration of the energy landscape; however, an a priori identification of a synthesis goal requires an exploration using theoretical methods. In contrast to those computational approaches currently employed for structure determination for fixed composition and already known unit cells, our aims clash with such restrictions and full global optimizations have to be performed on the landscape. Although for reasons of computational feasibility the accuracy of the energy calculations is not yet as high as one would wish, our approach proves to be surprisingly robust. One always finds the already known compounds of a given chemical system, and, in addition, further plausible structure candidates are discovered. The second step of a rational planning of syntheses is the design of feasible synthesis routes. Modeling such routes requires highly accurate computations for realistic thermodynamic conditions, however this is usually beyond our current capabilities. Thus, we have not seriously pursued such a deductive approach; instead we have attempted, to reproduce the "computational annealing" employed during our structure predictions in the experiment. Educts, generated by vapor deposition methods, that are disperse on an atomic level are found to react with surprisingly low activation energies to give highly crystallized products. However, even this technique does not yet provide the possibility to selectively synthesize a specific solid compound. For this final step, modeling and experimental control of nucleation processes will be the key ingredient. Only when viewed superficially, our goal of a "rational design" of solid-state syntheses and the "high-throughput" syntheses are in contradiction. But an exhaustive exploration of the unimaginably large combinatorial diversity of chemistry remains beyond our capabilities, even with an exceedingly high throughput. The future of solid-state synthesis will be found in a union of these two conceptual approaches.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Martin Jansen. 2002-10-18. A concept for synthesis planning in solid-state chemistry.. https://doi.org/10.1002/1521-3773(20021018)41%3A20%3C3746%3A%3Aaid-anie3746%3E3.0.co%3B2-2

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗